The CVC market is projected to grow from USD 2,861.0 million in 2024 to USD 5,436.8 million by 2034 at a CAGR of 6.6%.

Central venous catheter-related blood stream infection (CRBSI) is a major cause of morbidity and mortality in patients with end-stage renal disease treated with chronic hemodialysis. Risk factors ...

Use of high-dose (46.7%) sodium citrate locks for central venous catheters (CVCs) being used for maintenance hemodialysis provides no advantage over 5% heparin locks in reducing infections or ...